MktsMarkets

Lantern Pharma Inc.
NASDAQ: LTRNKey statistics
LTRN News
Stories mentioning LTRN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,725 | 2,745 | 2,437 | 3,068 | 3,264 | 4,269 | 3,717 | 3,889 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 3,405 | 4,202 | 4,350 | 4,652 | 4,774 | 5,896 | 5,180 | 5,408 |
| Operating Income (Loss) | (3,405) | (4,202) | (4,350) | (4,652) | (4,774) | (5,896) | (5,180) | (5,408) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 34.00 | 57.00 | 71.00 | 206.00 | 87.00 | (140.00) | 483.00 | 260.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (3,329) | (4,074) | (4,177) | (4,331) | (4,537) | (5,874) | (4,506) | (4,960) |
| Earnings Per Share (Basic) | (0.30) | (0.37) | (0.39) | (0.40) | (0.42) | (0.55) | (0.42) | (0.46) |
| Earnings Per Share (Diluted) | (0.30) | (0.37) | (0.39) | (0.40) | (0.42) | (0.55) | (0.42) | (0.46) |
| Weighted Average Shares Outstanding (Basic) | 11,253 | 10,898 | 10,833 | 10,785 | 10,785 | 10,762 | 10,763 | 10,759 |
| Weighted Average Shares Outstanding (Diluted) | 11,253 | 10,898 | 10,833 | 10,785 | 10,785 | 10,762 | 10,763 | 10,759 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About LTRN
Lantern Pharma Inc. (NASDAQ: LTRN) is a stock listed on the Nasdaq Stock Market under the ticker symbol LTRN. It last traded at $0.6600 (Oct 30, 2026, 4:00 PM ET), down 9.6% on the day. That gives Lantern Pharma a market capitalisation of $9.9M.
Over the past 52 weeks LTRN has traded between $0.5900 and $4.34.
For the quarter ended Mar 31, 2026 it reported a net loss of $3.3M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$3.3M |
| Dec 31, 2025 | — | -$4.1M |
| Sep 30, 2025 | — | -$4.2M |
| Jun 30, 2025 | — | -$4.3M |
From Lantern Pharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…